000281867 001__ 281867
000281867 005__ 20251127141341.0
000281867 0247_ $$2doi$$a10.1007/s12975-025-01388-4
000281867 0247_ $$2pmid$$apmid:41057606
000281867 0247_ $$2ISSN$$a1868-4483
000281867 0247_ $$2ISSN$$a1868-601X
000281867 037__ $$aDZNE-2025-01238
000281867 041__ $$aEnglish
000281867 082__ $$a610
000281867 1001_ $$aGiesers, Naomi K$$b0
000281867 245__ $$aAssociations of Soluble Inflammatory and Endothelial Activation Biomarkers with Cognitive Function Over Three Years After Ischemic Stroke-PROSCIS-B.
000281867 260__ $$aNew York, NY$$bSpringer$$c2025
000281867 3367_ $$2DRIVER$$aarticle
000281867 3367_ $$2DataCite$$aOutput Types/Journal article
000281867 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764249099_8032
000281867 3367_ $$2BibTeX$$aARTICLE
000281867 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281867 3367_ $$00$$2EndNote$$aJournal Article
000281867 520__ $$aVascular inflammation is involved in the pathophysiology of post-stroke cognitive impairment. We aimed to assess whether blood-based biomarkers of inflammation and endothelial dysfunction, such as interleukin 6 (IL-6), vascular cell adhesion molecule (VCAM-1), and tumor necrosis factor-alpha (TNF-α), are associated with cognitive function over time in a prospective cohort of first-ever ischemic stroke patients. Data were obtained from the Prospective Cohort with Incident Stroke Berlin (NCT01363856). Cognitive function was assessed with the Telephone Interview for Cognitive Status-modified (TICS-m) at 1 to 3 years of follow-up. Associations of baseline levels of IL-6, VCAM-1, and TNF-α with cognitive function over time were estimated using a linear mixed model adjusted for demographics, education, vascular risk factors, stroke severity, ischemic stroke subtype, and severity of white matter hyperintensity. We included 570 patients with mild-to-moderate ischemic stroke and baseline data on biomarker levels. The mean age was 67 (± 12 SD), 38.6% were female, and the median National Institutes of Health Stroke Scale (NIHSS) was 2 (IQR 1-4). Frequency of cognitive impairment defined as TICS-m score ≤ 31 was 21.9% at year one, 15.4% at year two, and 11.6% at year three. Higher log-transformed levels of IL-6 and VCAM-1 were associated with lower TICS-m scores over time in the adjusted linear mixed model including white matter hyperintensity burden (IL-6: β = -2.0, 95% CI -3.3 to -0.7, p = 0.003; VCAM-1: β = -4.1, 95% CI -7.3 to -1.0, p = 0.01). In patients with mild-to-moderate first-ever ischemic stroke, higher baseline levels of IL-6 and VCAM-1 were associated with lower Telephone Interview for Cognitive Status-modified during 3 years of follow-up.ClinicalTrials.gov Identifier: NCT01363856.
000281867 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281867 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281867 650_7 $$2Other$$aEndothelial dysfunction
000281867 650_7 $$2Other$$aInflammation
000281867 650_7 $$2Other$$aIschemic stroke
000281867 650_7 $$2Other$$aPost stroke cognitive impairment
000281867 650_7 $$2NLM Chemicals$$aBiomarkers
000281867 650_7 $$2NLM Chemicals$$aVascular Cell Adhesion Molecule-1
000281867 650_7 $$2NLM Chemicals$$aInterleukin-6
000281867 650_7 $$2NLM Chemicals$$aTumor Necrosis Factor-alpha
000281867 650_2 $$2MeSH$$aHumans
000281867 650_2 $$2MeSH$$aFemale
000281867 650_2 $$2MeSH$$aMale
000281867 650_2 $$2MeSH$$aAged
000281867 650_2 $$2MeSH$$aBiomarkers: blood
000281867 650_2 $$2MeSH$$aIschemic Stroke: blood
000281867 650_2 $$2MeSH$$aIschemic Stroke: complications
000281867 650_2 $$2MeSH$$aIschemic Stroke: psychology
000281867 650_2 $$2MeSH$$aMiddle Aged
000281867 650_2 $$2MeSH$$aVascular Cell Adhesion Molecule-1: blood
000281867 650_2 $$2MeSH$$aInterleukin-6: blood
000281867 650_2 $$2MeSH$$aProspective Studies
000281867 650_2 $$2MeSH$$aInflammation: blood
000281867 650_2 $$2MeSH$$aCognition: physiology
000281867 650_2 $$2MeSH$$aCognitive Dysfunction: blood
000281867 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000281867 650_2 $$2MeSH$$aTumor Necrosis Factor-alpha: blood
000281867 650_2 $$2MeSH$$aFollow-Up Studies
000281867 7001_ $$aSchaeff, Viktoria$$b1
000281867 7001_ $$aGertz, Karen$$b2
000281867 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b3$$udzne
000281867 7001_ $$0P:(DE-2719)9000189$$aLiman, Thomas G$$b4$$eLast author$$udzne
000281867 773__ $$0PERI:(DE-600)2541897-X$$a10.1007/s12975-025-01388-4$$gVol. 16, no. 6, p. 2249 - 2257$$n6$$p2249 - 2257$$tTranslational stroke research$$v16$$x1868-4483$$y2025
000281867 8564_ $$uhttps://pub.dzne.de/record/281867/files/DZNE-2025-01238%20SUP.docx
000281867 8564_ $$uhttps://pub.dzne.de/record/281867/files/DZNE-2025-01238.pdf
000281867 8564_ $$uhttps://pub.dzne.de/record/281867/files/DZNE-2025-01238%20SUP.doc
000281867 8564_ $$uhttps://pub.dzne.de/record/281867/files/DZNE-2025-01238%20SUP.odt
000281867 8564_ $$uhttps://pub.dzne.de/record/281867/files/DZNE-2025-01238%20SUP.pdf
000281867 8564_ $$uhttps://pub.dzne.de/record/281867/files/DZNE-2025-01238.pdf?subformat=pdfa$$xpdfa
000281867 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000281867 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000189$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000281867 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281867 9141_ $$y2025
000281867 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-31$$wger
000281867 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-31$$wger
000281867 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRANSL STROKE RES : 2022$$d2024-12-31
000281867 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-31
000281867 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-31
000281867 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-31
000281867 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-31
000281867 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-31
000281867 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-31
000281867 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-31
000281867 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bTRANSL STROKE RES : 2022$$d2024-12-31
000281867 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x0
000281867 980__ $$ajournal
000281867 980__ $$aVDB
000281867 980__ $$aI:(DE-2719)1811005
000281867 980__ $$aUNRESTRICTED